The phase 3 Keynote-181 study assessing Keytruda as monotherapy in the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma has achieved a primary endpoint of … Continue reading Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial